亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study

医学 酪氨酸激酶 药理学 酪氨酸激酶抑制剂 激酶 内科学 免疫病理学 免疫学 临床研究阶段 酶抑制剂 临床试验 不利影响 癌症研究 化疗 毒性 肿瘤科
作者
Xu Yao,Yi Liu,Yang Luo,Xiaochun Liu,Min Zhou,Bin Yang,Lunfei Liu,Linfeng Li,Weijun Liu,X. Man,A. Chen,Yuling Shi,Yangfeng Ding,Qing Sun,Juan Tao,Jingjing Chen,Congxin Liang,Qianjin Lu
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:195 (2): 222-231 被引量:1
标识
DOI:10.1093/bjd/ljag092
摘要

BACKGROUND: Chronic spontaneous urticaria (CSU) places a considerable burden on both patients and caregivers. Current treatments for CSU are inadequate for some patients. TLL-018, an oral tyrosine kinase 2/Janus kinase 1 (TYK2/JAK1) inhibitor, is currently being investigated as a potential treatment for CSU. OBJECTIVES: To evaluate the efficacy and safety of TLL-018 for treating moderate-to-severe CSU in patients with an inadequate response to antihistamines. METHODS: In this multicentre, double-blind, randomized, placebo-controlled, parallel-group pilot study (NCT05373355), patients with CSU who showed an inadequate response to antihistamines were given (1: 1: 1) 10 or 30 mg of TLL-018, or placebo, orally twice daily. After 4 weeks, patients on placebo were switched to TLL-018 20 mg and continued treatment for a further 8 weeks. The primary endpoint was safety, while secondary endpoints included efficacy measures, such as weekly Urticaria Activity Score (UAS7) ≤ 6, UAS7 = 0, and a Dermatology Life Quality Index score of 0 or 1, at weeks 4 and 12. RESULTS: Overall, 41 patients were randomly assigned to TLL-018 10 mg (n = 14), 30 mg (n = 13) or placebo (n = 14). At week 4, the placebo-adjusted change from baseline (analysed using Ancova) in UAS7, weekly Itch Severity Score and weekly Hive Severity Score was -11.5, -8.0 and -3.8, respectively, in the 10-mg TLL-018 group, and -16.0, -9.0 and -7.0, respectively, in the 30-mg group. At week 12, the proportions of patients achieving UAS7 ≤ 6 and UAS7 = 0 were 54% and 39%, respectively, in the placebo-then-20-mg group, 71% and 64% in the 10-mg group, and 62% and 54% in the 30-mg group. Common treatment-emergent adverse events included elevated serum creatine kinase and blood lipid levels, hyperglycaemia and urinary occult blood. CONCLUSIONS: TLL-018 was well tolerated and effective in treating moderate-to-severe CSU in patients who had an inadequate response to antihistamines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小医发布了新的文献求助10
2秒前
4秒前
xl的应助被高高采纳,获得20
4秒前
筑梦之鱼完成签到,获得积分10
6秒前
6秒前
内啡呔发布了新的文献求助10
8秒前
9秒前
噔噔噔噔完成签到,获得积分10
11秒前
奔跑的应助被研猫采纳,获得10
14秒前
老六完成签到 ,获得积分10
14秒前
噔噔噔噔发布了新的文献求助10
15秒前
纯情的阁发布了新的文献求助10
17秒前
zc完成签到,获得积分10
17秒前
小二郎的应助被小医采纳,获得10
18秒前
纯情的阁发布了新的文献求助10
19秒前
19秒前
19秒前
纯情的阁发布了新的文献求助10
20秒前
纯情的阁发布了新的文献求助50
20秒前
纯情的阁发布了新的文献求助10
20秒前
纯情的阁发布了新的文献求助50
21秒前
纯情的阁发布了新的文献求助10
23秒前
纯情的阁发布了新的文献求助10
23秒前
纯情的阁发布了新的文献求助10
23秒前
纯情的阁发布了新的文献求助50
24秒前
rex发布了新的文献求助10
25秒前
英姑的应助被舒心梦菲采纳,获得10
25秒前
幸福的沛萍完成签到,获得积分10
26秒前
纯情的阁发布了新的文献求助10
26秒前
纯情的阁发布了新的文献求助10
27秒前
纯情的阁发布了新的文献求助10
27秒前
纯情的阁发布了新的文献求助10
27秒前
古木完成签到,获得积分10
29秒前
29秒前
纯情的阁发布了新的文献求助10
30秒前
纯情的阁发布了新的文献求助50
30秒前
纯情的阁发布了新的文献求助10
30秒前
纯情的阁发布了新的文献求助10
31秒前
纯情的阁发布了新的文献求助10
31秒前
椰子云发布了新的文献求助10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158582
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719049
捐赠科研通 7748110
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551881
邀请新用户注册赠送积分活动 2471262